Meredith S Shiels1, Hormuzd A Katki2, Neal D Freedman2, Mark P Purdue2, Nicolas Wentzensen2, Britton Trabert2, Cari M Kitahara2, Michael Furr2, Yan Li2, Troy J Kemp2, James J Goedert2, Cindy M Chang2, Eric A Engels2, Neil E Caporaso2, Ligia A Pinto2, Allan Hildesheim2, Anil K Chaturvedi2. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD (MSS, HAK, NDF, MPP, NW, BT, CMK, JJG, EAE, NEC, AH, ANK); Information Management Services, Inc, Rockville, MD (MF); Joint Program for Survey Methodology, University of Maryland, College Park, MD (YL); Leidos Biomedical Research, Inc., Frederick, MD (TJK, LAP); Center for Tobacco Products, Food and Drug Administration, Rockville, MD (CMC). shielsms@mail.nih.gov. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD (MSS, HAK, NDF, MPP, NW, BT, CMK, JJG, EAE, NEC, AH, ANK); Information Management Services, Inc, Rockville, MD (MF); Joint Program for Survey Methodology, University of Maryland, College Park, MD (YL); Leidos Biomedical Research, Inc., Frederick, MD (TJK, LAP); Center for Tobacco Products, Food and Drug Administration, Rockville, MD (CMC).
Abstract
BACKGROUND: A comprehensive characterization of the effects of cigarette smoke on systemic soluble immune/inflammatory markers may provide insight into the mechanisms through which smoking causes disease. METHODS: Levels of 78 inflammation, immune, and metabolic markers were measured using multiplex immune assays in 1819 Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) participants aged 55 to 74 years from three existing nested case-control studies. These data were made representative of the entire PLCO screening arm through reweighting with weights estimated in logistic regression models. We assessed associations between smoking status, cigarettes smoked per day, and time since quitting with dichotomized marker levels using adjusted weighted logistic regression models. RESULTS: Current smoking was associated with 10 inflammation markers after correcting for multiple testing, encompassing several components of the immune/inflammation response. Levels of seven of these markers (interleukin [IL]-15, IL-1RA, IL-1β, IL-16, stem cell factor, soluble interleukin 6 receptor, and soluble vascular endothelial growth factor receptor 3) were lower among current smokers (n = 414) when compared with never smokers (n = 548), with odds ratios (ORs) ranging from 0.44 to 0.27, while levels of CC motif ligand (CCL)/thymus and activation regulated chemokine (CCL17/TARC) (OR = 4.08, 95% confidence interval [CI] = 2.01 to 8.25), CCL11/EOTAXIN (OR = 2.57, 95% CI = 1.45 to 4.55), and C-reactive protein (CRP) (OR = 2.54, 95% CI = 1.29 to 4.98) were elevated. These markers were not associated with cigarettes per day among current smokers, but there were trends in IL-15, IL-1RA, IL-1β, CCL17/TARC, CCL11/EOTAXIN, and CRP levels across categories of years since quitting smoking. CONCLUSIONS: Smoking is associated with a broad range of alterations in systemic immune and inflammation marker levels among older, long-term smokers. Smoking cessation may result in marker levels reverting back to those of never smokers over time. Published by Oxford University Press 2014.
BACKGROUND: A comprehensive characterization of the effects of cigarette smoke on systemic soluble immune/inflammatory markers may provide insight into the mechanisms through which smoking causes disease. METHODS: Levels of 78 inflammation, immune, and metabolic markers were measured using multiplex immune assays in 1819 Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) participants aged 55 to 74 years from three existing nested case-control studies. These data were made representative of the entire PLCO screening arm through reweighting with weights estimated in logistic regression models. We assessed associations between smoking status, cigarettes smoked per day, and time since quitting with dichotomized marker levels using adjusted weighted logistic regression models. RESULTS: Current smoking was associated with 10 inflammation markers after correcting for multiple testing, encompassing several components of the immune/inflammation response. Levels of seven of these markers (interleukin [IL]-15, IL-1RA, IL-1β, IL-16, stem cell factor, soluble interleukin 6 receptor, and soluble vascular endothelial growth factor receptor 3) were lower among current smokers (n = 414) when compared with never smokers (n = 548), with odds ratios (ORs) ranging from 0.44 to 0.27, while levels of CC motif ligand (CCL)/thymus and activation regulated chemokine (CCL17/TARC) (OR = 4.08, 95% confidence interval [CI] = 2.01 to 8.25), CCL11/EOTAXIN (OR = 2.57, 95% CI = 1.45 to 4.55), and C-reactive protein (CRP) (OR = 2.54, 95% CI = 1.29 to 4.98) were elevated. These markers were not associated with cigarettes per day among current smokers, but there were trends in IL-15, IL-1RA, IL-1β, CCL17/TARC, CCL11/EOTAXIN, and CRP levels across categories of years since quitting smoking. CONCLUSIONS: Smoking is associated with a broad range of alterations in systemic immune and inflammation marker levels among older, long-term smokers. Smoking cessation may result in marker levels reverting back to those of never smokers over time. Published by Oxford University Press 2014.
Authors: Britton Trabert; Ligia Pinto; Patricia Hartge; Troy Kemp; Amanda Black; Mark E Sherman; Louise A Brinton; Ruth M Pfeiffer; Meredith S Shiels; Anil K Chaturvedi; Allan Hildesheim; Nicolas Wentzensen Journal: Gynecol Oncol Date: 2014-08-23 Impact factor: 5.482
Authors: S Goya Wannamethee; Gordon D O Lowe; A Gerald Shaper; Ann Rumley; Lucy Lennon; Peter H Whincup Journal: Eur Heart J Date: 2005-04-07 Impact factor: 29.983
Authors: Anil K Chaturvedi; Troy J Kemp; Ruth M Pfeiffer; Angelique Biancotto; Marcus Williams; Stella Munuo; Mark P Purdue; Ann W Hsing; Ligia Pinto; J Philip McCoy; Allan Hildesheim Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-06-29 Impact factor: 4.254
Authors: Erikka Loftfield; Meredith S Shiels; Barry I Graubard; Hormuzd A Katki; Anil K Chaturvedi; Britton Trabert; Ligia A Pinto; Troy J Kemp; Fatma M Shebl; Susan T Mayne; Nicolas Wentzensen; Mark P Purdue; Allan Hildesheim; Rashmi Sinha; Neal D Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-21 Impact factor: 4.254
Authors: Fangcheng Yuan; Lin Deng; Xiangqing Sun; Zhengyi Chen; Nitin Shivappa; Ashutosh K Sheth; Gregory S Cooper; James R Hebert; Li Li Journal: Cancer Causes Control Date: 2021-04-29 Impact factor: 2.506
Authors: Lauren C Peres; James R Hebert; Bo Qin; Kristin A Guertin; Elisa V Bandera; Nitin Shivappa; Tareq F Camacho; Deanna Chyn; Anthony J Alberg; Jill S Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Joellen M Schildkraut Journal: J Nutr Date: 2019-09-01 Impact factor: 4.798
Authors: Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar Journal: Am J Physiol Heart Circ Physiol Date: 2019-02-01 Impact factor: 4.733
Authors: Baiyu Yang; Jessica L Petrick; Jake E Thistle; Ligia A Pinto; Troy J Kemp; Hao Quang Tran; Andrew T Gewirtz; Tim Waterboer; Veronika Fedirko; Mazda Jenab; Barry I Graubard; Stephanie J Weinstein; Demetrius Albanes; Katherine A McGlynn Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-01-02 Impact factor: 4.254